How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

5,119 results for

Benign Prostatic Hyperplasia

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Benign Prostatic Hyperplasia: Surgical Management of Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms

Benign Prostatic Hyperplasia: Surgical Management of Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms Benign Prostatic Hyperplasia (BPH) Guideline - American Urological Association advertisement Toggle navigation About Us About the AUA Membership AUA Governance Industry Relations Education AUAUniversity Education Products & Resources Normal Histology and Important Histo-anatomic Structures Urinary Bladder Prostate Kidney Renovascular Diseases Andrenal Gland Testis Paratesticular Tumors (...) Resources Coding and Reimbursement Practice Managers' Network (PMN) Patient Safety and Quality of Care Accreditations and Reporting Patient Education Benign Prostatic Hyperplasia: Surgical Management of Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms (2018, amended 2019) Published 2018, Amended 2019 The goal of this revised guideline is to provide a useful reference on the effective evidence-based surgical management of male lower urinary tract symptoms secondary to benign prostatic

2019 American Urological Association

2. Benign Prostatic Hyperplasia: Surgical Management of Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms

Benign Prostatic Hyperplasia: Surgical Management of Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms 1 Purpose Benign prostatic hyperplasia (BPH) is a histologic diagnosis that refers to the proliferation of smooth muscle and epithelial cells within the prostatic transition zone. The prevalence and the severity of lower urinary tract symptoms (LUTS) in the aging male can be progressive and is an important diagnosis in the healthcare of patients and the welfare of society (...) Urological Association (AUA) Surgical Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA GUIDELINE Harris E. Foster, MD; Michael J. Barry, MD; Philipp Dahm, MD; Manhar C. Gandhi, MD; Steven A. Kaplan, MD; Tobias S. Kohler, MD; Lori B. Lerner, MD; Deb J. Lightner, MD; J. Kellogg Parsons, MD; Claus G. Roehrborn, MD; Charles Welliver, MD; Timothy J. Wilt, MD; Kevin T. McVary, MD Copyright © 2019 American Urological Association Education and Research, Inc.® 2 American

2019 American Urological Association

3. Prostatic urethral temporary implant insertion for lower urinary tract symptoms caused by benign prostatic hyperplasia

Prostatic urethral temporary implant insertion for lower urinary tract symptoms caused by benign prostatic hyperplasia Prostatic urethr Prostatic urethral tempor al temporary implant insertion ary implant insertion for lower urinary tr for lower urinary tract symptoms caused b act symptoms caused by y benign prostatic h benign prostatic hyperplasia yperplasia Interventional procedures guidance Published: 30 January 2019 nice.org.uk/guidance/ipg641 Y Y our responsibility our responsibility (...) NICE recommendations wherever possible. 1 1 Recommendations Recommendations 1.1 Current evidence on the safety and efficacy of prostatic urethral temporary implant insertion for lower urinary tract symptoms caused by benign prostatic hyperplasia is limited in quantity and quality. Therefore, this procedure should © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 1 of 4only be used in the context of research. 1.2

2019 National Institute for Health and Clinical Excellence - Interventional Procedures

4. Prostate artery embolisation for lower urinary tract symptoms caused by benign prostatic hyperplasia

Prostate artery embolisation for lower urinary tract symptoms caused by benign prostatic hyperplasia Prostate artery embolisation for lower urinary Prostate artery embolisation for lower urinary tr tract symptoms caused b act symptoms caused by benign prostatic y benign prostatic h hyperplasia yperplasia Interventional procedures guidance Published: 24 April 2018 nice.org.uk/guidance/ipg611 Y Y our responsibility our responsibility This guidance represents the view of NICE, arrived at after (...) Recommendations Recommendations 1.1 Current evidence on the safety and efficacy of prostate artery embolisation for benign prostatic hyperplasia is adequate to support the use of this procedure © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 1 of 4provided that standard arrangements are in place for clinical governance, consent and audit. 1.2 Patient selection should be done by a urologist and an interventional radiologist

2018 National Institute for Health and Clinical Excellence - Interventional Procedures

5. Aquablation of the prostate for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. (PubMed)

Aquablation of the prostate for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. New, minimally invasive surgeries have emerged as alternatives to transurethral resection of the prostate (TURP) for the management of lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH). Aquablation is a novel, minimally invasive, water-based therapy, combining image guidance and robotics for the removal of prostatic tissue.To assess the effects (...) of Aquablation for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.We performed a comprehensive search using multiple databases (the Cochrane Library, MEDLINE, Embase, Scopus, Web of Science, and LILACS), trials registries, other sources of grey literature, and conference proceedings published up to 11 February 2019, with no restrictions on the language or status of publication.We included parallel-group randomised controlled trials (RCTs) and cluster-RCTs, as well

2019 Cochrane

6. Prostatic urethral lift for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. (PubMed)

Prostatic urethral lift for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. A variety of minimally invasive surgical approaches are available as an alternative to transurethral resection of prostate (TURP) for the management of lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH). A recent addition to these is prostatic urethral lift (PUL).To assess the effects of PUL for the treatment of LUTS in men with BPH.We performed (...) not find any non-RCTs.Two review authors independently screened the literature, extracted data, and assessed risk of bias. We performed statistical analyses using a random-effects model and interpreted them according to the Cochrane Handbook for Systematic Reviews of Interventions. We planned subgroup analyses by age, prostate volume, and severity of baseline symptoms. We used the GRADE approach to rate the certainty of the evidence.We included two RCTs with 297 participants comparing PUL to sham

2019 Cochrane Controlled trial quality: predicted high

7. Endoscopic non-contact (side-firing) visual laser ablation of the prostate (VLAP) for benign prostatic hyperplasia (BPH)

Endoscopic non-contact (side-firing) visual laser ablation of the prostate (VLAP) for benign prostatic hyperplasia (BPH) 1 Public Summary Document Application No. 1518 – Endoscopic visual laser ablation of the prostate (VLAP) for benign prostatic hyperplasia Applicant: Boston Scientific Date of MSAC consideration: MSAC 75 th Meeting, 28-29 March 2019 Context for decision: MSAC makes its advice in accordance with its Terms of Reference, visit the MSAC website 1. Purpose of application (...) An application examining the evidence to support an increase in the Medicare Benefits Schedule (MBS) fee for endoscopic visual laser ablation of the prostate (VLAP), also known as photoselective vaporisation of the prostate [PVP] for men with benign prostate hyperplasia (BPH) was received from Boston Scientific Pty Ltd by the Department of Health. 2. MSAC’s advice to the Minister After considering the strength of the available evidence in relation to comparative safety, clinical effectiveness and cost

2019 Medical Services Advisory Committee

8. Transurethral water vapour ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia

Transurethral water vapour ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia T T r ransurethr ansurethral water vapour ablation for lower al water vapour ablation for lower urinary tr urinary tract symptoms caused b act symptoms caused by benign y benign prostatic h prostatic hyperplasia yperplasia Interventional procedures guidance Published: 21 August 2018 nice.org.uk/guidance/ipg625 Y Y our responsibility our responsibility This guidance represents the view (...) possible. 1 1 Recommendations Recommendations 1.1 Current evidence on the safety and efficacy of transurethral water vapour ablation for urinary tract symptoms caused by benign prostatic hyperplasia is © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 1 of 4adequate to support the use of this procedure provided that standard arrangements are in place for clinical governance, consent and audit. 1.2 This procedure should

2018 National Institute for Health and Clinical Excellence - Interventional Procedures

9. Transurethral water jet ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia

Transurethral water jet ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia T T r ransurethr ansurethral water jet ablation for lower urinary al water jet ablation for lower urinary tr tract symptoms caused b act symptoms caused by benign prostatic y benign prostatic h hyperplasia yperplasia Interventional procedures guidance Published: 19 September 2018 nice.org.uk/guidance/ipg629 Y Y our responsibility our responsibility This guidance represents the view of NICE (...) possible. 1 1 Recommendations Recommendations 1.1 The evidence on transurethral water jet ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia raises no major safety concerns. The evidence on efficacy is limited in quantity. Therefore, this © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 1 of 5procedure should only be used with special arrangements for clinical governance, consent, and audit

2018 National Institute for Health and Clinical Excellence - Interventional Procedures

10. Society of Interventional Radiology Multisociety Consensus Position Statement on Prostatic Artery Embolization for Treatment of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia

Society of Interventional Radiology Multisociety Consensus Position Statement on Prostatic Artery Embolization for Treatment of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia Society of Interventional Radiology Multisociety Consensus Position Statement on Prostatic Artery Embolization for Treatment of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: From the Society of Interventional Radiology, the Cardiovascular and Interventional Radiological (...) Attributed to Benign Prostatic Hyperplasia: From the Society of Interventional Radiology, the Cardiovascular and Interventional Radiological Society of Europe, Société Française de Radiologie, and the British Society of Interventional Radiology Endorsed by the Asia Pacific Society of Cardiovascular and Interventional Radiology, Canadian Association for Interventional Radiology, Chinese College of Interventionalists, Interventional Radiology Society of Australasia, Japanese Society of Interventional

Full Text available with Trip Pro

2019 Society of Interventional Radiology

11. Minimally-Invasive Treatments for Lower Urinary Tract Symptoms in People with Benign Prostatic Hyperplasia: A Review of Clinical Effectiveness

Minimally-Invasive Treatments for Lower Urinary Tract Symptoms in People with Benign Prostatic Hyperplasia: A Review of Clinical Effectiveness Minimally-Invasive Treatments for Lower Urinary Tract Symptoms in People with Benign Prostatic Hyperplasia: A Review of Clinical Effectiveness | CADTH.ca Find the information you need Minimally-Invasive Treatments for Lower Urinary Tract Symptoms in People with Benign Prostatic Hyperplasia: A Review of Clinical Effectiveness Minimally-Invasive Treatments (...) for Lower Urinary Tract Symptoms in People with Benign Prostatic Hyperplasia: A Review of Clinical Effectiveness Last updated: August 29, 2019 Project Number: RC1172-000 Product Line: Research Type: Devices and Systems Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of select minimally-invasive treatments for the management of lower urinary tract symptoms in people with benign prostatic hyperplasia? Key Message Four recent systematic reviews

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

12. Silodosin Recordati - benign prostatic hyperplasia (BPH)

Silodosin Recordati - benign prostatic hyperplasia (BPH) 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. EMA/815843/2018 EMEA/H/C/004964 Silodosin Recordati (silodosin) An overview of Silodosin Recordati and why it is authorised (...) in the EU What is Silodosin Recordati and what is it used for? Silodosin Recordati is a medicine used to treat the symptoms of benign prostatic hyperplasia (BPH, an enlarged prostate gland) in adults. The prostate gland is an organ found at the base of the bladder in men. When enlarged, it can cause problems with the flow of urine. This medicine is identical to Urorec, which has been authorised in the EU since 29 January 2010. How is Silodosin Recordati used? Silodosin Recordati can only be obtained

2019 European Medicines Agency - EPARs

15. Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia. (PubMed)

Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia. Benign prostatic hyperplasia (BPH) refers to non-malignant enlargement of the prostate gland that may cause bothersome lower urinary tract symptoms (LUTS). Alpha-blockers (ABs) and 5-alpha reductase inhibitors (5-ARIs) are the mainstay of medical treatment. Recently, phosphodiesterase inhibitors (PDEIs) that so far have been used mainly to treat erectile dysfunction were introduced (...) reflecting more symptoms), urinary bother as assessed by the Benign Prostatic Hyperplasia Impact Index (BPHII; score ranging from 0 to 13, with higher values reflecting more bother), and adverse events (AEs). We used GRADE to rate the quality of evidence. We considered short-term (up to 12 weeks) and long-term (12 weeks or longer) results separately.We included a total of 16 randomised trials in this review. The results for primary outcomes are as follows.PDEI versus placebo: PDEIs may result in a small

2018 Cochrane

16. Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia. (PubMed)

Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia. Benign prostatic hyperplasia (BPH) is a common condition in ageing men that may cause lower urinary tract symptoms (LUTS). Treatment aims are to relieve symptoms and prevent disease-related complications. Naftopidil is an alpha-blocker (AB) that has a high affinity for the A1d receptor that may have advantages in treating LUTS in this setting. This is an update of a Cochrane Review first (...) years, prostate volume was 35.4 mL, and International Prostate Symptom Score was 18.3. We were unable to perform any of the preplanned subgroup analyses based on age and baseline symptom score.Naftopidil versus tamsulosinBased on 12 studies with 965 randomised participants, naftopidil may have resulted in little or no difference in urological symptom score (mean difference (MD) 0.47, 95% confidence interval (CI) -0.09 to 1.04 measured on a scale from 0 to 35 with higher score representing increased

2018 Cochrane

17. Benign prostatic hyperplasia

Benign prostatic hyperplasia Benign prostatic hyperplasia - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Benign prostatic hyperplasia Last reviewed: February 2019 Last updated: September 2018 Summary Multi-factorial involving smooth muscle hyperplasia, prostatic enlargement, and bladder dysfunction, as well as input from the central nervous system. Presents with both storage symptoms (frequency, urgency, nocturia (...) invasive therapy. Failure of medical management or renal complications are indications for surgical intervention. There are a host of procedural treatments, which have unique risk/benefit profiles for consideration. Definition Lower urinary tract symptoms (LUTS) caused by bladder outlet obstruction due to benign prostatic hyperplasia (BPH), also known as benign prostatic enlargement (BPE), are predominantly due to 2 components: a static component related to an increase in benign prostatic tissue

2018 BMJ Best Practice

18. Benign prostatic hyperplasia

Benign prostatic hyperplasia Benign prostatic hyperplasia - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Benign prostatic hyperplasia Last reviewed: February 2019 Last updated: September 2018 Summary Multi-factorial involving smooth muscle hyperplasia, prostatic enlargement, and bladder dysfunction, as well as input from the central nervous system. Presents with both storage symptoms (frequency, urgency, nocturia (...) invasive therapy. Failure of medical management or renal complications are indications for surgical intervention. There are a host of procedural treatments, which have unique risk/benefit profiles for consideration. Definition Lower urinary tract symptoms (LUTS) caused by bladder outlet obstruction due to benign prostatic hyperplasia (BPH), also known as benign prostatic enlargement (BPE), are predominantly due to 2 components: a static component related to an increase in benign prostatic tissue

2018 BMJ Best Practice

19. Prostate artery embolisation for benign prostatic hyperplasia

Prostate artery embolisation for benign prostatic hyperplasia Prostate artery embolisation for benign prostatic hyperplasia Prostate artery embolisation for benign prostatic hyperplasia Vreugdenburg T, Wild C Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Vreugdenburg T, Wild C. Prostate artery embolisation for benign prostatic (...) commonly reported side effects associated with PAE in all studies were minor. Currently, five RCTs are ongoing comparing PAE to TURP, the end of which is scheduled for February 2021. A new evaluation is proposed in the year 2021, if results from RCTs are available by then. Project page URL Final publication URL Additional data URL Indexing Status Subject indexing assigned by CRD MeSH Arteries; Embolization, Therapeutic; Humans; Male; Prostate-Specific Antigen; Prostatic Hyperplasia Language Published

2017 Health Technology Assessment (HTA) Database.

20. Lower Urinary Tract Symptoms-Suspicion of Benign Prostatic Hyperplasia

Lower Urinary Tract Symptoms-Suspicion of Benign Prostatic Hyperplasia Date of origin: 1995 Last review date: 2014 ACR Appropriateness Criteria ® 1 Lower Urinary Tract Symptoms: Suspicion of BPH American College of Radiology ACR Appropriateness Criteria ® Clinical Condition: Lower Urinary Tract Symptoms: Suspicion of Benign Prostatic Hyperplasia Radiologic Procedure Rating Comments RRL* US pelvis (bladder and prostate) transabdominal 6 Consider this procedure after patient voids to measure (...) without IV contrast 1 ???? CT abdomen and pelvis with IV contrast 1 ???? Rating Scale: 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate *Relative Radiation Level ACR Appropriateness Criteria ® 2 Lower Urinary Tract Symptoms: Suspicion of BPH LOWER URINARY TRACT SYMPTOMS: SUSPICION OF BENIGN PROSTATIC HYPERPLASIA Expert Panel on Urologic Imaging: Barak Friedman, MD 1 ; John R. Leyendecker, MD 2 ; M. Donald Blaufox, MD, PhD 3 ; Steven C. Eberhardt, MD 4 ; Pat F. Fulgham

2019 American College of Radiology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>